公开(公告)号：US20220396629A1

公开(公告)日：2022-12-15

申请号：US17825202

申请日：2022-05-26

Applicant: GENMAB A/S

Inventor： Paul PARREN ,  Janine Schuurman ,  Tom Vink ,  Willem Karel Bleeker ,  Jan Van De Winkel ,  Patrick Van Berkel ,  Frank Beurskens

IPC: C07K16/28

Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

公开(公告)号：US10351629B2

公开(公告)日：2019-07-16

申请号：US15072983

申请日：2016-03-17

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Paul Parren ,  Willem Karel Bleeker ,  Frank Beurskens ,  Patrick Van Berkel

IPC: C07K16/00 ,  A61K39/00 ,  C12N15/85 ,  C07K16/28

Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

公开(公告)号：US20190169311A1

公开(公告)日：2019-06-06

申请号：US15998816

申请日：2018-08-16

Applicant: Genmab A/S

Inventor： Sandra Verploegen ,  David P.E. Satijn ,  Rene M.A. Hoet ,  Paul Parren ,  Jan Van De Winkel ,  Vibeke Miller Breinholt ,  Eva Ehrnrooth ,  Ole Baadsgaard ,  Tom Vink ,  Willem Karel Bleeker ,  Mischa Houtkamp ,  Maroeska Oudshoorn ,  Rob N. De Jong

IPC: C07K16/36 ,  A61K39/395

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US09714297B2

公开(公告)日：2017-07-25

申请号：US14839514

申请日：2015-08-28

Applicant: GENMAB A/S

Inventor： Sandra Verploegen ,  David P. E. Satijn ,  Rene M. A. Hoet ,  Paul Parren ,  Jan Van De Winkel ,  Vibeke Miller Breinholt ,  Eva Ehrnrooth ,  Ole Baadsgaard ,  Tom Vink ,  Willem Karel Bleeker ,  Mischa Houtkamp ,  Maroeska Oudshoorn ,  Rob N. De Jong

IPC: C07K16/36 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/36 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US09540450B2

公开(公告)日：2017-01-10

申请号：US14199391

申请日：2014-03-06

Applicant: GENMAB A/S

Inventor： Jan Van De Winkel ,  Paul Parren ,  Willem Karel Bleeker ,  Klaus Edvardsen ,  Jeroen Lammerts Van Bueren ,  Thomas Valerius ,  Michael Dechant ,  Wencke Weisner ,  Sven Berger

IPC: C07K16/28 ,  C07K16/40 ,  C07K16/44 ,  C07K16/46 ,  G01N33/573 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573

Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.

Abstract translation: 本发明涉及用于治疗肿瘤的新方法，包括施用双特异性抗体或两种或多种识别相同靶抗原或抗原复合物的非交叉阻断抗体的组合。 特别地，本发明涉及用于诱导补体介导的细胞杀伤治疗肿瘤的方法，所述方法包括向有需要的人共同施用第一抗体和第二抗体，其中所述第一抗体 结合EGFR，所述第二抗体结合EGFR，所述第一和第二抗体是非交叉阻断的，并且所述给药方案使得在肿瘤部位获得CDC。